암 바이오마커 시장 규모, 점유율, 성장 분석 : 바이오마커 종류별, 암 종류별, 기술별, 용도별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Global Cancer Biomarkers Market size was valued at USD 26.61 billion in 2024 and is poised to grow from USD 29.75 billion in 2025 to USD 72.61 billion by 2033, growing at a CAGR of 11.8% during the forecast period (2026-2033).

The increasing prevalence of cancer globally is anticipated to drive a heightened demand for cancer biomarkers. Significant investment in oncology research and growing awareness of the advantages of biomarkers in cancer diagnosis and treatment are expected to unlock new opportunities for companies in this sector. The rise in gene therapies and personalized medicine will likely further enhance the utilization of cancer biomarkers. Additionally, advancements in biomarker research and a growing preference for non-invasive and minimally invasive procedures are projected to benefit the market. Conversely, challenges such as issues related to clinical validity and reproducibility, limited awareness among healthcare professionals, ethical concerns, and stringent regulatory requirements may hinder future market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cancer Biomarkers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cancer Biomarkers Market Segments Analysis

Global Cancer Biomarkers Market is segmented by Biomarker Type, Cancer Type, Technology, Application, End User and region. Based on Biomarker Type, the market is segmented into Genetic Biomarkers, Protein Biomarkers, Metabolic Biomarkers, Cell-based Biomarkers, Imaging Biomarkers and Others. Based on Cancer Type, the market is segmented into Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer, Liver Cancer, Blood Cancer (Leukemia, Lymphoma, Myeloma) and Others. Based on Technology, the market is segmented into Omics Technologies, Immunoassays, PCR (Polymerase Chain Reaction), Next Generation Sequencing (NGS), Imaging Techniques and Others. Based on Application, the market is segmented into Diagnostics, Prognostics, Drug Discovery & Development, Personalized Medicine and Research Applications. Based on End User, the market is segmented into Hospitals & Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Research & Academic Institutes, Contract Research Organizations (CROs) and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Cancer Biomarkers Market

One key market driver for the global cancer biomarkers market is the increasing prevalence of cancer and the rising demand for early diagnostic and personalized treatment solutions. As awareness of cancer's impact on public health grows, the urgency for effective screening methods and targeted therapies becomes more pronounced. Advances in biotechnology and genomics have significantly enhanced biomarker discovery, facilitating the development of innovative diagnostic tools that enable precise patient stratification and treatment optimization. Additionally, supportive government initiatives and increased funding for cancer research further bolster the growth of this market, as stakeholders seek to provide effective solutions for cancer management.

Restraints in the Global Cancer Biomarkers Market

One key market restraint for the global cancer biomarkers market is the high cost of research and development associated with biomarker discovery and validation. Many cancer biomarkers require extensive studies, clinical trials, and regulatory approvals, which can be both time-consuming and expensive. The financial burden of these processes often limits the ability of smaller biotech firms to enter the market and compete, resulting in a slower pace of innovation and potentially restricted patient access to advanced diagnostic tests. Additionally, reimbursement challenges for biomarker-based tests further complicate market growth, leading to hesitance among healthcare providers and patients alike.

Market Trends of the Global Cancer Biomarkers Market

The Global Cancer Biomarkers market is witnessing a significant trend towards the adoption of a multi-omics approach in biomarker development. This strategy leverages the integration of various omics disciplines-genomics, transcriptomics, proteomics, metabolomics, and epigenomics-to create comprehensive biomarker signatures that enhance specificity and efficacy. By moving beyond traditional methods that focus on isolated analytes, the multi-omics approach provides a holistic view of the molecular landscape of cancer. This innovation accelerates the advancement of precision oncology, improving the clinical utility and diagnostic accuracy of cancer biomarkers, thereby positioning companies that embrace this strategy as leaders in a competitive market.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Technology Assessment

Global Cancer Biomarkers Market Size by Biomarker Type & CAGR (2026-2033)

• Market Overview
• Genetic Biomarkers
• Protein Biomarkers
• Metabolic Biomarkers
• Cell-based Biomarkers
• Imaging Biomarkers
• Others

Global Cancer Biomarkers Market Size by Cancer Type & CAGR (2026-2033)

• Market Overview
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Cervical Cancer
• Liver Cancer
• Blood Cancer (Leukemia, Lymphoma, Myeloma)
• Others

Global Cancer Biomarkers Market Size by Technology & CAGR (2026-2033)

• Market Overview
• Omics Technologies
  • Genomics
  • Proteomics
  • Metabolomics
• Immunoassays
• PCR (Polymerase Chain Reaction)
• Next Generation Sequencing (NGS)
• Imaging Techniques
• Others

Global Cancer Biomarkers Market Size by Application & CAGR (2026-2033)

• Market Overview
• Diagnostics
• Prognostics
• Drug Discovery & Development
• Personalized Medicine
• Research Applications

Global Cancer Biomarkers Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals & Diagnostic Laboratories
• Pharmaceutical & Biotechnology Companies
• Research & Academic Institutes
• Contract Research Organizations (CROs)
• Others

Global Cancer Biomarkers Market Size & CAGR (2026-2033)

• North America (Biomarker Type, Cancer Type, Technology, Application, End User)
  • US
  • Canada
• Europe (Biomarker Type, Cancer Type, Technology, Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Biomarker Type, Cancer Type, Technology, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Biomarker Type, Cancer Type, Technology, Application, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Biomarker Type, Cancer Type, Technology, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• F. Hoffmann-La Roche Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN N.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PerkinElmer, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hologic, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exact Sciences Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guardant Health, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Techne Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genomic Health, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fujirebio Holdings, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations